July 22, 2013
Nuvilex Delivery Platform May Emerge As The Holy Grail To Cancer Treatment
A number of biotech and pharmaceutical firms have switched gears in their effort to successfully fight cancer. In addition to developing drugs that directly or indirectly fight cancer cells, or could be potentially used as a preventive measure, many firms are focusing their attention on devising more effective drug delivery methods. Perhaps these firms are following in the footsteps of Nuvilex, Inc. (OTCQB – NVLX - $0.15 – Spec Buy). Nuvilex is an international firm engaged in using its live-cell encapsulation technology to develop treatments for pancreatic and other cancers along with the examining the use of constituents of medical marijuana to develop treatments for oncology patients.
Earlier this year, nanomedicine-based firms executed successful clinical trials and engaged in large development deals with some of the world’s leading drug giants. These firms have demonstrated an ability to encapsulate potent drugs in tiny particles measuring billionths of a meter in diameter; this technology is opening up new options for super-accurate drug delivery, increasing precision hits at the site of disease with limited side effects. This is a similar concept to Nuvilex’s approach where cells containing high levels of enzymes that activate pro-drugs to their cancer-killing forms are encapsulated and placed in proximity to the tumor and therefore, the cancer drugs are targeted directly at the tumor with greater efficacy than traditional methods and with far less drug-related toxicity.
In July of this year, researchers at Purdue University announced that they have developed a concept to potentially improve delivery of drugs for cancer treatment using nanoparticles that concentrate and expand in the presence of higher acidity found in tumor cells.
The concept involves using nanoparticles made of "weak polybases," compounds that expand when transported into environments mimicking tumor cells, which have a higher acidity than surrounding tissues. The researchers used sophisticated modeling to show how the particles would accumulate in regions of higher acidity and remain there long enough to deliver anticancer drugs.
Whether one is referring to high-profile nanomedicine-based firms or pre-clinical university research, the fact that drug delivery is at the forefront of the fight against cancer bodes well for Nuvilex, which has already demonstrated significant efficacy and low toxicity in its Phase II inoperable pancreatic cancer trials. Moreover, it should capture the attention of new investors and prospective partners as well.
You Might Also Like
Senior Analyst: Robert Goldman
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.